Table 1 Clinical manifestations at disease onset of KawaCOVID Group (KCG) of patients and Kawasaki Disease Group (KDG) of patients
KCG (n = 53) N (%) | KDG (n = 96) N (%) | p value | |
|---|---|---|---|
Skin involvement | |||
Maculo-papular rash | 21 (40) | 59 (62) | 0·001 |
Erythema multiforme | 4 (8) | 7 (7) | 1 |
Scarlatiniform rash | 0 (0) | 8 (8) | 0·05 |
Hands and feet erythema/oedema | 15 (28) | 38 (40) | 0·17 |
Hands and feet desquamation | 1 (2) | 6 (6) | 0·42 |
Perineal Erythema/Desquamation | 0 (0) | 8 (8) | 0·05 |
Mucosal involvement | |||
Cheilitis | 14 (26) | 46 (48) | 0·01 |
Pharyngeal and/or oral erhytema | 24 (45) | 49 (51) | 0·50 |
Strawberry tongue | 4 (8) | 14 (15) | 0·29 |
Ocular involvement | |||
Non Secretive Conjunctivitis | 27 (51) | 67 (70) | 0·02 |
Neurological involvement | |||
Headache | 5 (9) | 3 (3) | 0·13 |
Consciousness abnormalities | 4 (8) | 1 (1) | 0·05 |
Aseptic meningitis | 3 (6) | 1 (1) | 0·13 |
Irritability | 8 (15) | 34 (35) | 0·01 |
Gastrointestinal involvement | |||
Diarrhea | 28 (53) | 11 (12) | < 0·0001 |
Vomiting | 14 (26) | 8 (8) | 0·003 |
Abdominal pain | 17 (32) | 10 (10) | 0·001 |
Gallbladder hydrops | 2 (4) | 3 (3) | 1 |
Respiratory involvement | |||
Dyspnea | 8 (15) | 1 (1) | 0·001 |
Tachypnea | 12 (23) | 4 (4) | 0·001 |
Cough | 3 (6) | 10 (10) | 0·38 |
Rhinitis | 0 (0) | 5 (5) | 0·16 |
Lobar pneumonia | 3 (6) | 2 (2) | 0·35 |
Interstitial pneumonia | 20 (37) | 17 (18) | 0·01 |
O2 supplementation | 14 (28) | 2 (2) | < 0·0001 |
Ventilation | 6 (12) | 0 (0) | 0·003 |
Osteoarticular involvement | |||
Arthritis and/or arthralgia | 6 (11) | 13 (14) | 0·7 |